Trost Susanne, Pratley Richard, Sobel Burton
Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, One South Prospect Street, Burlington, VT 05401, USA.
Curr Diab Rep. 2006 Feb;6(1):47-54. doi: 10.1007/s11892-006-0052-5.
Patients with the metabolic syndrome are insulin resistant and manifest a cluster of risk factors for cardiovascular disease. Impaired fibrinolysis and increased concentrations in blood of plasminogen activator inhibitor-1 (PAI-1) are related to insulin resistance and abdominal obesity and may contribute to the increased risk for cardiovascular disease in this group. Weight loss, metformin, and thiazolidinediones ameliorate insulin resistance and decrease concentrations of PAI-1. Thus, they may lower risk in patients with the metabolic syndrome.
患有代谢综合征的患者存在胰岛素抵抗，并表现出一系列心血管疾病风险因素。纤维蛋白溶解功能受损以及纤溶酶原激活物抑制剂-1（PAI-1）血液浓度升高与胰岛素抵抗和腹型肥胖相关，可能导致该群体心血管疾病风险增加。体重减轻、二甲双胍和噻唑烷二酮类药物可改善胰岛素抵抗并降低PAI-1浓度。因此，它们可能降低代谢综合征患者的风险。
